Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
METHODS OF USING A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND/OR ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND/OR ACTIVATED COAGULATION FACTOR X
Document Type and Number:
WIPO Patent Application WO/2018/047813
Kind Code:
A1
Abstract:
An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.

Inventors:
YONEYAMA KOICHIRO (JP)
SCHMITT CHRISTOPHE (CH)
Application Number:
PCT/JP2017/031933
Publication Date:
March 15, 2018
Filing Date:
September 05, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
HOFFMANN LA ROCHE (CH)
International Classes:
A61K39/395; A61P7/04
Domestic Patent References:
WO2015194233A12015-12-23
Other References:
SHIMA, M. ET AL.: "Long-term safety and prophylactic efficacy of once-weekly subcutaneous administration of ACE910 , in Japanese hemophilia A patients with and without FVIII inhibitors: interim results of the extension study of a phase 1 study", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 13, no. 2, 2015, pages 6 - 7, XP009513701, ISSN: 1538-7933, DOI: 10.1111/jth.12993
See also references of EP 3509637A4
Attorney, Agent or Firm:
HARUNA, Masao et al. (JP)
Download PDF: